WG
FLNA

Winton Group’s Filana Therapeutics FLNA Stock Holding History

Winton Group’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-44,089
Closed -$507K – 1486
2020
Q3 		$507K Buy
44,089
+12,469
+39% +$56.2K 0.02% 1108
2020
Q2 		$97K Buy
+31,620
New +$143K ﹤0.01% 1402

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Winton Group's FLNA Position: Q4 2020 in Review

Winton Group sold out of Filana Therapeutics (FLNA) in Q4 2020, closing a stake of 44,089 shares — an estimated $507K sold.

Winton Group first reported a position in FLNA in Q2 2020 and held it in 2 quarters. The position peaked at $507K in Q3 2020. 79 funds tracked by Wall St. Rank hold FLNA as of Q4 2020.

  • Winton Group reported no remaining Filana Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Winton Group sold 44,089 Filana Therapeutics shares in Q4 2020, an estimated $507K.
  • Winton Group first reported a position in Filana Therapeutics in Q2 2020 and held it in 2 quarters.
  • Winton Group's Filana Therapeutics position peaked at $507K in Q3 2020.
  • 79 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2020.

Based on Winton Group's 13F filing for Q4 2020, filed 12 Feb 2021.